Advances in hydroxamic acid hybrids for liver cancer therapy: a decade of progress (2016-2025)

Area of Science:

• Oncology
• Medicinal Chemistry
• Epigenetics

Background:

• Liver cancer is a leading cause of cancer death, often diagnosed late and progressing rapidly.
• Current chemotherapy for liver cancer faces challenges including drug resistance, poor efficacy, and toxicity.
• Histone deacetylase (HDAC) inhibitors, utilizing hydroxamic acid as a zinc-binding group, are crucial in cancer therapy.

Purpose of the Study:

• To explore novel hydroxamic acid hybrids as potential chemotherapeutic agents for liver cancer.
• To investigate the multitarget efficacy and resistance-overcoming capabilities of these compounds.
• To assess their therapeutic versatility for next-generation liver cancer treatments.

Main Methods:

• Development of hydroxamic acid hybrids through modular pharmacophore integration.
• Evaluation of epigenetic potency and multitarget efficacy.
• Assessment of resistance-overcoming properties and therapeutic versatility in preclinical models (details not provided in abstract).

Main Results:

• Hydroxamic acid hybrids demonstrated potential as effective anti-liver cancer agents.
• These compounds exhibit multitarget efficacy and the ability to overcome existing drug resistance mechanisms.
• The modular design offers therapeutic versatility for liver cancer treatment.

Conclusions:

• Hydroxamic acid hybrids are promising candidates for next-generation liver cancer therapies.
• Their ability to harness epigenetic mechanisms and overcome resistance addresses critical unmet needs.
• Further research and development are warranted to translate these findings into clinical applications.